Pharmaceutical News

EMA Recommends Trivalent Vaccines for 2024 Influenza Season EU EMA The EMA recommends shifting from quadrivalent to trivalent influenza vaccines for 2024, excluding the B/Yamagata strain. New guidelines aim to boost seasonal flu vaccine effectiveness.
FDA Approves Bkemv as First Interchangeable Biosimilar to Soliris FDA FDA approves Bkemv (eculizumab-aeeb), the first interchangeable biosimilar to Soliris, for treating rare diseases like PNH and aHUS, enhancing treatment access.
FDA Approves Biosimilars Yesafili and Opuviz FDA Aflibercept FDA approves Yesafili and Opuviz as interchangeable biosimilars to Eylea, offering new treatments for wet AMD, macular edema, and diabetic retinopathy.
FDA Approves First Drug for Wild Quail Treatment" FDA Discover the FDA's first-ever approval of Safe-Guard (fenbendazole) for treating gastrointestinal worms in wild quail, a breakthrough for wildlife management.
Pfizer's First-Quarter 2024 Financial statements Financial statements Pifzer Pfizer published its Q1 2024 financial statements on May 1, 2024.
AbbVie's First-Quarter 2024 Financial statements Financial statements AbbVie AbbVie published its Q1 2024 financial statements on April 26, 2024.
Johnson & Johnson's First-Quarter 2024 Financial statements Johnson & Johnson Financial statements Johnson & Johnson published its Q1 2024 financial statements on April 16, 2024.
Merck's First-Quarter 2024 Financial statements Financial statements Merck Merck published its Q1 2024 financial statements on April 25, 2024.
Novartis's First-Quarter 2024 Financial statements Financial statements Novartis Pfizer published its Q1 2024 financial statements on May 1, 2024.
Roche's First-Quarter 2024 Financial statements Financial statements Roche Roche published its Q1 2024 financial statements on April 24, 2024.